Dorothy B. Abel BSBME, AIMBE

Dorothy Abel is currently working as a Vice President of Regulatory Strategy Syntactx. Prior to joining NAMSA through the acquisition of Syntactx, Dorothy Abel had a highly accomplished 30+ year career with the U.S. Food and Drug Administration (FDA) within the Center for Devices and Radiological Health (CDRH). At the FDA, Dorothy led the evaluation of vascular and endovascular surgery devices and pioneered approaches for the evaluation of devices, including co-founding the Early Feasibility Study Program in collaboration with FDA colleagues, professional surgical societies, and international voluntary standards committees. Ms. Abel provides expert assistance in developing and communicating regulatory evaluation strategies and helps Clients achieve regulatory approvals and product adoption worldwide.